A trial of quizartinib for acute myeloid leukaemia (QuANTUM-R)
Cancer type:
Status:
Phase:
This trial looked at quizartinib for acute myeloid leukaemia (AML) that had got worse during treatment or come back after treatment.
It was open for people to join between 2014 and 2017. The team published results in 2019 and 2021. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Doctors often treat acute myeloid leukaemia (AML) with chemotherapy and then a bone marrow or stem cell transplant. But sometimes these treatments don’t work. Researchers wanted to find out if quizartinib can help people in this situation.
Quizartinib (AC220) is a type of targeted cancer treatment called a cancer growth blocker. It stops the signals that cancer cells use to divide and grow.
The people taking part were put into a treatment group at random:
- 2 out of every 3 people had quizartinib
- 1 out of every 3 people had standard chemotherapy
The main aim of this trial was to find out which treatment is better for AML that has got worse during treatment or come back within 6 months of treatment.
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the links below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E Cortes and others
Lancet Oncology, 2019. Volume 20, issue 7, pages 984-997.
Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Dongwoo Kang and others
Cancer Chemotherapy Pharmacology, 2021. Volume 87, issue 4, pages 513-523.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Nigel Russell
Supported by
Daiichi Sankyo
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
